The Alliance for Regenerative Medicine reported on 22 November that cell and gene therapy companies have raised enough money already in 2021 to break the record set in 2020. Venture capital financings are driving the surge with $8.2bn raised through the third quarter, which is up 45% from the same nine-month period last year.
Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
$8.2bn In VC Deals Through Q3 Is Up 45% Year-Over-Year
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
